| Basics |
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Ltd is a biotechnology company developing novel RNA medicines. The company develops novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases.
|
| IPO Date: |
May 22, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$484.71M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.99 | 3.84%
|
| Avg Daily Range (30 D): |
$0.66 | 4.41%
|
| Avg Daily Range (90 D): |
$0.51 | 3.70%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.38M |
| Avg Daily Volume (30 D): |
.53M |
| Avg Daily Volume (90 D): |
.41M |
| Trade Size |
| Avg Trade Size (Sh.): |
64 |
| Avg Trade Size (Sh.) (30 D): |
58 |
| Avg Trade Size (Sh.) (90 D): |
53 |
| Institutional Trades |
| Total Inst.Trades: |
2,008 |
| Avg Inst. Trade: |
$2.07M |
| Avg Inst. Trade (30 D): |
$1.23M |
| Avg Inst. Trade (90 D): |
$1.12M |
| Avg Inst. Trade Volume: |
.07M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.32M |
| Avg Closing Trade (30 D): |
$1.11M |
| Avg Closing Trade (90 D): |
$1.05M |
| Avg Closing Volume: |
77.9K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-2.23
|
$-.34
|
$-.52
|
|
Diluted EPS
|
$-2.22
|
$-.34
|
$-.52
|
|
Revenue
|
$ 122.12M
|
$ 28.3M
|
$ 29.38M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -60.16M
|
$ -9.18M
|
$ -14.08M
|
|
Operating Income / Loss
|
$ -72.57M
|
$ -11.62M
|
$ -16.83M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -63.86M
|
$ -20.48M
|
$ -20.08M
|
|
PE Ratio
|
|
|
|
|
|
|
